Citations

Showing 10 of 108135 citations.

Induced Pluripotent Stem Cells From Subjects With Primary Sclerosing Cholangitis Develop a Senescence Phenotype Following Biliary Differentiation
Jalan‐Sakrikar, Nidhi , Assuncao, Thiago M. de , Navarro‐Corcuera, Amaia , Hamdan, Feda H. , Loarca, Lorena, Kirkeby, Lindsey A., Resch, Zachary T., O’Hara, Steven P. , Juran, Brian D., Lazaridis, Konstantinos N. , Rosen, Charles B. , Taner, Timuçin , Shah, Vijay H. , De Assuncao, Thiago M, Taner, Timucin , Shah, Vijay H , Huebert, Robert , Lazaridis, Konstantinos N , Sakrikar, Nidhi Jalan , Heimbach, Julie K. , LaRusso, Nicholas F. , Huebert, Robert C.

Mayo Clinic

Hepatology Communications | August 26, 2021 | Volume: 6 | Issue: 2 | Pages: 345-360

10.1002/hep4.1809 | PMID 34519176 Get It

Primary sclerosing cholangitis (PSC) is a chronic fibroinflammatory disease of the biliary tract characterized by cellular senescence and periportal fibrogenesis. Specific disease features that are cell intrinsic and either genetically or epigenetically mediated remain unclear due in part to a lack of appropriate, patient‐specific, in vitro models. Recently, our group developed systems to create induced pluripotent stem cell (iPSC)‐derived cholangiocytes (iDCs) and biliary epithelial organoids (cholangioids). We use these models to investigate whether PSC cholangiocytes are intrinsically predisposed to cellular senescence. Skin fibroblasts from healthy controls and subjects with PSC were reprogrammed to pluripotency, differentiated to cholangiocytes, and subsequently grown in three‐dimensional matrigel‐based culture to induce formation of cholangioids. RNA sequencing (RNA‐seq) on iDCs showed significant differences in gene expression patterns, including enrichment of pathways associated with cell cycle, senescence, and hepatic fibrosis, that correlate with PSC. These pathways also overlapped with RNA‐seq analysis on isolated cholangiocytes from subjects with PSC. Exome sequencing on the subjects with PSC revealed genetic variants of unknown significance in the genes identified in these pathways. Three‐dimensional culture revealed smaller size, lack of a central lumen, and increased cellular senescence in PSC‐derived cholangioids. Congruent with this, PSC‐derived iDCs showed increased secretion of the extracellular matrix molecule fibronectin as well as the inflammatory cytokines interleukin‐6, and chemokine (C‐C motif) ligand 2. Conditioned media (CM) from PSC‐derived iDCs more potently activated hepatic stellate cells compared to control CM. Conclusion: We demonstrated efficient generation of iDCs and cholangioids from patients with PSC that show disease‐specific features. PSC cholangiocytes are intrinsically predisposed to cellular senescence. These features are unmasked following biliary differentiation of pluripotent stem cells and have functional consequences in epithelial organoids.
Therapeutic Underuse and Delay in Hepatocellular Carcinoma: Prevalence, Associated Factors, and Clinical Impact
Govalan, Rajalakshmi , Luu, Michael , Lauzon, Marie , Kosari, Kambiz , Ahn, Joseph , Rich, Nicole E. , Nissen, Nicholas N. , Roberts, Lewis R. , Yang, Ju Dong , Ahn, Joseph C , Yang, Ju Dong , Roberts, Lewis R , Singal, Amit G.

Mayo Clinic

Hepatology Communications | August 26, 2021 | Volume: 6 | Issue: 1 | Pages: 223-236

10.1002/hep4.1795 | PMID 34558830 Get It

Prognosis of hepatocellular carcinoma (HCC) could be affected by lack of or delayed therapy. We aimed to characterize the prevalence, correlates, and clinical impact of therapeutic underuse and delay in patients with HCC. Patients with HCC diagnosed between 2010 and 2017 were analyzed from the United States National Cancer Database. Logistic regression analysis identified factors associated with no and delayed (>90 days after diagnosis) HCC treatment. Cox proportional hazards regression with landmark analysis assessed the association between therapeutic delay and overall survival (OS), accounting for immortal time bias. Of 116,299 patients with HCC, 24.2% received no treatment and 18.4% of treated patients had delayed treatment. Older age, Black, Hispanic, lower socioeconomic status, earlier year of diagnosis, treatment at nonacademic centers, Northeast region, increased medical comorbidity, worse liver dysfunction, and higher tumor burden were associated with no treatment. Among treated patients, younger age, Hispanic, Black, treatment at academic centers, West region, earlier tumor stage, and receipt of noncurative treatment were associated with treatment delays. In multivariable Cox regression with a landmark of 150 days, patients with and without treatment delays had similar OS (adjusted hazard ratio [aHR], 1.01; 95% confidence interval [CI], 0.98‐1.04) with a median survival of 33.7 vs. 32.1 months, respectively. However, therapeutic delay was associated with worse OS in patients who had tumor, nodes, and metastases (TNM) stage 1 (aHR, 1.06; 95% CI, 1.01‐1.11) or received curative treatment (aHR, 1.12; 95% CI, 1.05‐1.18). Conclusion: One‐fourth of patients with HCC receive no therapy and one‐fifth of treated patients experience treatment delays. Both were associated with demographic, socioeconomic, and clinical characteristics of patients as well as facility type and region. The association between therapeutic delay and survival was stage and treatment dependent.
Baseline Cognitive Impairment in Patients With Asymptomatic Carotid Stenosis in the CREST-2 Trial
Lazar, Ronald M. , Wadley, Virginia G., Myers, Terina , Jones, Michael R., Heck, Donald V., Clark, Wayne M. , Marshall, Randolph S. , Howard, Virginia J., Voeks, Jenifer H., Manly, Jennifer J. , Moy, Claudia S., Chaturvedi, Seemant, Meschia, James F., Lal, Brajesh K. , Brott, Thomas G., Howard, George, Howard, Virginia J. , Howard, Virginia J , Manly, Jennifer J , Lazar, Ronald M , Wadley, Virginia G., Myers, Terina , Jones, Michael R., Heck, Donald V., Clark, Wayne M. , Marshall, Randolph S. , Voeks, Jenifer H., Moy, Claudia S., Chaturvedi, Seemant, Meschia, James F., Lal, Brajesh , Brott, Thomas G., Howard, George

Mayo Clinic

Stroke | August 26, 2021 | Volume: 52 | Issue: 12 | Pages: 3855-3863

10.1161/strokeaha.120.032972 | PMID 34433306 Get It

Background and Purpose: Studies of carotid artery disease have suggested that high-grade stenosis can affect cognition, even without stroke. The presence and degree of cognitive impairment in such patients have not been reported and compared with a demographically matched population-based cohort. Methods: We studied cognition in 1000 consecutive CREST-2 (Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial) patients, a treatment trial for asymptomatic carotid disease. Cognitive assessment was after randomization but before assigned treatment. The cognitive battery was developed in the general population REGARDS Study (Reasons for Geographic and Racial Differences in Stroke), involving Word List Learning Sum, Word List Recall, and Word List fluency for animal names and the letter F. The carotid stenosis patients were >45 years old with ≥70% asymptomatic carotid stenosis and no history of prevalent stroke. The distribution of cognitive performance for the patients was standardized, accounting for age, race, and education using performance from REGARDS, and after further adjustment for hypertension, diabetes, dyslipidemia, and smoking. Using the Wald Test, we tabulated the proportion of Z scores less than the anticipated deviate for the population-based cohort for representative percentiles. Results: There were 786 baseline assessments. Mean age was 70 years, 58% men, and 52% right-sided stenosis. The overall Z score for patients was significantly below expected for higher percentiles ( P <0.0001 for 50th, 75th, and 95th percentiles) and marginally below expected for the 25th percentile ( P =0.015). Lower performance was attributed largely to Word List Recall ( P <0.0001 for all percentiles) and for Word List Learning (50th, 75th, and 95th percentiles below expected, P ≤0.01). The scores for left versus right carotid disease were similar. Conclusions: Baseline cognition of patients with severe carotid stenosis showed below normal cognition compared to the population-based cohort, controlling for demographic and cardiovascular risk factors. This cohort represents the largest group to date to demonstrate that poorer cognition, especially memory, in this disease. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02089217.
Delayed-Onset Heparin-Induced Thrombocytopenia With Cerebral Venous Sinus Thrombosis Following Total Knee Arthroplasty: Case Report
Bauman, Megan M. J. , Naylor, Ryan M. , Santilli, Ashley R. , Wijdicks, Eelco F., Bauman, Megan , Wijdicks, Eelco F. M.

Mayo Clinic

The Neurohospitalist | August 26, 2021 | Volume: 12 | Issue: 2 | Pages: 328-331

10.1177/19418744211042966 | PMID 35419157 Get It

Heparin-induced thrombocytopenia (HIT) is a prothrombotic state caused by autoantibodies against platelet factor 4 (PF4)-heparin complexes. Although HIT typically presents 5-10 days after the initiation of heparin, thrombosis and thrombocytopenia may occur up to several weeks following heparin withdrawal, so-called delayed-onset HIT. Although rare, there have been isolated reports of HIT-induced cerebral venous sinus thrombosis (CVST), which carry high rates of morbidity and mortality. There is a need to further characterize the etiology, clinical presentation, treatment paradigms, and outcomes of patients with HIT-induced CVST. Here, we present the case of a 57-year old female who presented to the emergency department with a headache and seizure 11 days following a right total knee arthroplasty for which she received 3 post-operative doses of enoxaparin. Work-up demonstrated acute intracerebral hemorrhage (ICH), CVST, and thrombocytopenia. Intravenous heparin resulted in rapidly deteriorating platelet count and subsequent serologic testing confirmed the diagnosis of HIT. Treatment with bivalirudin was initiated, the HIT resolved, and the patient was discharged home on hospital day 19 with long-term anticoagulation mediated by warfarin. At 3-month follow up, the patient had mild upper motor neuron pattern weakness and was living independently. This case depicts a rare case of delayed-onset HIT and CVST, highlights the importance of establishing a fluid treatment plan for managing HIT-induced CVST, and illustrates the importance of employing rapid anticoagulation despite acute ICH to achieve a desirable clinical outcome.
Epidemiology, risk factors, and association of antifungal prophylaxis on early invasive fungal infection in heart transplant recipients
Yetmar, Zachary A. , Lahr, Brian D. , Brumble, Lisa , Gea‐Banacloche, Juan , Steidley, D. Eric , Kushwaha, Sudhir S. , Beam, Elena , Lahr, Brian , Kushwaha, Sudhir , Yetmar, Zachary A , Beam, Elena

Mayo Clinic

Transplant Infectious Disease | August 26, 2021 | Volume: 23 | Issue: 5 | Pages: No page available

10.1111/tid.13714 | PMID 34435415 Get It

Abstract Background Invasive fungal infection (IFI) in heart transplant recipients is associated with poor outcomes. Estimated risk of 1‐year IFI in heart transplant recipients is 3.4–8.6% with risk factors inconsistently identified in previous studies. The role of antifungal prophylaxis is unclear. The transplant program at Mayo Clinic provides 6 months of universal azole prophylaxis for those heart transplant recipients in Arizona. We sought to define risk factors for 1‐year IFI and determine the effect of antifungal prophylaxis. Methods We conducted a retrospective cohort study of patients undergoing heart transplantation at Mayo Clinic from January 2000 to March 2019. We analyzed demographics, details of transplant hospitalization, antifungal prophylaxis, and fungal infection. Multivariable Cox analyses were performed to identify risk factors of 1‐year IFI and impact of IFI on posttransplant mortality. Results A total of 966 heart transplant recipients were identified with a median age of 56 years (IQR 47, 62). A total of 444 patients received antifungal prophylaxis. Over 1‐year follow‐up, 62 patients developed IFI with a cumulative incidence of 6.4%. In multivariable analysis, factors associated with IFI were renal replacement therapy (RRT) (HR 3.24, 95% CI 1.65–6.39), allograft rejection (HR 2.33, 95% CI 1.25–4.34), and antifungal prophylaxis (HR 0.32, 95% CI 0.11–0.96). RRT was also associated with invasive mold infection (HR 3.00, 95% CI 1.29–6.97). Conclusions RRT and allograft rejection after transplantation are associated with 1‐year IFI, and RRT is also associated with invasive mold infection. Antifungal prophylaxis appears to be protective and further study is needed in the heart transplant population.
Interaction Time with Electronic Health Records: A Systematic Review
Pinevich, Yuliya , Clark, Kathryn J. , Harrison, Andrew M. , Pickering, Brian W. , Harrison, Andrew Marc , Clark, Kathryn , Herasevich, Vitaly

Mayo Clinic

Applied Clinical Informatics | August 25, 2021 | Volume: 12 | Issue: 04 | Pages: 788-799

10.1055/s-0041-1733909 | PMID 34433218 Get It

Abstract Background The amount of time that health care clinicians (physicians and nurses) spend interacting with the electronic health record is not well understood. Objective This study aimed to evaluate the time that health care providers spend interacting with electronic health records (EHR). Methods Data are retrieved from Ovid MEDLINE(R) and Epub Ahead of Print, In-Process and Other Non-Indexed Citations and Daily, (Ovid) Embase, CINAHL, and SCOPUS. Study Eligibility Criteria Peer-reviewed studies that describe the use of EHR and include measurement of time either in hours, minutes, or in the percentage of a clinician's workday. Papers were written in English and published between 1990 and 2021. Participants All physicians and nurses involved in inpatient and outpatient settings. Study Appraisal and Synthesis Methods A narrative synthesis of the results, providing summaries of interaction time with EHR. The studies were rated according to Quality Assessment Tool for Studies with Diverse Designs. Results Out of 5,133 de-duplicated references identified through database searching, 18 met inclusion criteria. Most were time-motion studies (50%) that followed by logged-based analysis (44%). Most were conducted in the United States (94%) and examined a clinician workflow in the inpatient settings (83%). The average time was nearly 37% of time of their workday by physicians in both inpatient and outpatient settings and 22% of the workday by nurses in inpatient settings. The studies showed methodological heterogeneity. Conclusion This systematic review evaluates the time that health care providers spend interacting with EHR. Interaction time with EHR varies depending on clinicians' roles and clinical settings, computer systems, and users' experience. The average time spent by physicians on EHR exceeded one-third of their workday. The finding is a possible indicator that the EHR has room for usability, functionality improvement, and workflow optimization.
The interplay between gray matter and white matter neurodegeneration in subjective cognitive decline
Cedrés, Nira , Diaz‐Galvan, Patricia , Muehlboeck, J‐Sebastian, Barroso, José , Westman, Eric , Westman, Eric , Diaz-Galvan, Patricia , Díaz‐Flores, Lucio , Molina, Yaiza , Ferreira, Daniel

Mayo Clinic

Aging | August 25, 2021 | Volume: 13 | Issue: 16 | Pages: 19963-19977

10.18632/aging.203467 | PMID 34433132 Get It

International remote collaboration enabled inaugural endoscopic sleeve gastroplasty in Japan
Dobashi, Akira , Uno, Kohei , Matsui, Hiroaki , Furuhashi, Hiroto , Futakuchi, Toshiki , Kamba, Shunsuke , Ono, Shingo , Tamai, Naoto , Watanabe, Atsushi , Gostout, Christopher J., Sumiyama, Kazuki , Uno, Kohei

Mayo Clinic

DEN Open | August 25, 2021 | Volume: 2 | Issue: 1 | Pages: No page available

10.1002/deo2.31 | PMID 35310731 Get It

AbstractObesity causes multiple conditions such as type 2 diabetes, cardiovascular disease, and so on, and an intervention is needed for controlling weight and improving metabolic syndrome. However, the effectiveness of lifestyle interventions and pharmacotherapy are restrictive for losing weight. Endoscopic sleeve gastroplasty (ESG) was developed as a new therapy, picking the best of both medication and surgery, less invasive and more effective. Recently, ESG is gradually spreading in Western countries, but there is Case report doesn't need conclusion/result for Japanese patients. We herein reported the first clinical case of ESG in Japan.Given the situation of the pandemic of COVID‐19, we could not invite a proctor from Western countries and receive the instruction of the device setting and maneuver face to face. Thus, we conducted the training for device setting, maneuver, and operation under a web‐based international remote collaboration. Eventually, we completed ESG without an adverse event. We could prove this web‐based proctor system was useful through the introduction of ESG in Japan. The international remote collaboration could become a new normal even in the endoscopy field post‐COVID‐19 era.
Update on the Basic Science Concepts and Applications of Adipose-Derived Stem Cells in Hand and Craniofacial Surgery
Lynch, Evan B. , Anderson, Wes, DeCoster, Ryan , Bonaroti, Alisha R., Vyas, Krishna S. , Vásconez, Henry C., Lin, Kant Y., Anderson, W Matthew, DeCoster, Ryan C , Bourne, Debra A, Bourne, Debra A.

Mayo Clinic

Plastic & Reconstructive Surgery | August 25, 2021 | Volume: 148 | Issue: 3 | Pages: 475e-486e

10.1097/prs.0000000000008279 | PMID 34432707 Get It

Summary: Adipose-derived stem cell therapy offers plastic surgeons a novel treatment alternative for conditions with few therapeutic options. Adipose-derived stem cells are a promising treatment because of their broad differentiation potential, capacity for self-renewal, and ease of isolation. Over the past decade, plastic surgeons have attempted to harness adipose-derived stem cells’ unique cellular characteristics to improve the survival of traditional fat grafting procedures, a process known as cell-assisted lipotransfer. However, the full implications of cell-assisted lipotransfer in clinical practice remain incompletely understood, stressing the urgent need to assess the scientific evidence supporting adipose-derived stem cell–based interventions. Furthermore, with the strict regulatory climate surrounding tissue explantation therapies, reviewing the safety and efficacy of these treatments will clarify their regulatory viability moving forward. In this report, the authors provide a comprehensive, up-to-date appraisal of best evidence-based practices supporting adipose-derived stem cell–derived therapies, highlighting the known mechanisms behind current clinical applications in tissue engineering and regenerative medicine specific to plastic and reconstructive surgery. The authors outline best practices for the harvest and isolation of adipose-derived stem cells and discuss why procedure standardization will elucidate the scientific bases for their broad use. Finally, the authors discuss challenges posed by U.S. Food and Drug Administration oversight of these cell-based therapies and examine the role of adipose-derived stem cell–based applications in the future of plastic surgery.